Research programme: T cell therapy - BrightPath Biotherapeutics

Drug Profile

Research programme: T cell therapy - BrightPath Biotherapeutics

Alternative Names: iPS-T; iPS-T(rejT); rejT; T cell therapy - BrightPath Biotherapeutics

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BrightPath Biotherapeutics
  • Class Antineoplastics; Immunotherapies; Stem cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Lymphoma

Most Recent Events

  • 03 Oct 2017 BrightPath Biotherapeutics and Juntendo University agree to co-develop T cell therapies for Lymphoma
  • 11 Jul 2017 Early research in Lymphoma in Japan (Parenteral), before July 2017 (BrightPath Biotherapeutics website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top